A longevity protocol is not a single cycle — it is a layered annual architecture where different peptides address different aging mechanisms on different timescales. Some interventions are run continuously (the hormonal foundation), some in long seasonal blocks (mitochondrial and tissue repair), and some in short targeted bursts (telomere and neurological reset).
The organizing principle is non-redundancy and sequencing. Every peptide in the stack hits a mechanistically distinct target. Nothing is doubled up. And the order matters — you lay the metabolic and hormonal foundation first, then layer mitochondrial reset, then structural tissue repair, then neurological maintenance. Epithalon runs as a burst course 2–3× per year across all other layers as the cellular aging anchor.
This stack is not aggressive — it is restorative. The goal is to bring aging systems back toward youthful baseline function, not to supraphysiologically push any single axis. Every peptide here works through the body's own endogenous pathways.
| Peptide | Dose | Route | Frequency | Timing | Cycle |
|---|---|---|---|---|---|
| Epithalon | 5 mg | SC | Daily (course) | Pre-bed | 10–20 days, 2–3×/yr |
| CJC-1295 | 200–300 mcg | SC | Daily | Pre-bed fasted | 3–6 mo on / 1–2 mo off |
| Ipamorelin | 200–300 mcg | SC | Daily | Pre-bed fasted | Same as CJC |
| SS-31 | 10–30 mg | SC | Daily | AM | 8–12 wk, 2×/yr |
| MOTS-c | 100–300 mcg | SC | 3–5×/week | AM fasted / pre-WO | 12 wk, 2×/yr |
| 5-Amino-1MQ | 100–200 mg | Oral | Daily | AM with food | 8–16 wk, 2×/yr |
| GHK-Cu | 1–3 mg | SC + topical | 5–7×/wk (inj) | AM | 12–16 wk, 2×/yr |
| BPC-157 | 250–500 mcg | SC | Daily | AM | 4–8 wk, 2×/yr |
| TB-500 | 2–5 mg | SC | 2–3×/wk load, 1×/wk maintain | AM | 6–8 wk, 2×/yr |
| Semax (N-Ac Amid) | 100–300 mcg | Nasal | Daily | AM only | 2–4 wk, 2–3×/yr |
| Selank | 250–500 mcg | SC or nasal | Daily | AM + pre-bed | 2–4 wk, 2–3×/yr |
Run a comprehensive baseline before starting the protocol. Retest at 6 months and 12 months. Specific biomarkers should also be tested at the start and end of each individual cycle block.
| Biomarker | Test | Clinical | Optimal Goal |
|---|---|---|---|
| Telomere Length Primary Epithalon marker | LifeLength / Teloyears | CLINICALDeclines with age | GOALAt or above median; lengthening trend year-over-year |
| Biological Age | TruAge / DunedinPACE | CLINICALWithin ±5 yrs chronological | GOAL5–10 yrs below chronological; slowing pace annually |
| IGF-1 | Serum IGF-1 | CLINICAL115–355 ng/mL | GOALUpper third of age range (~200–300 ng/mL) — CJC/Ipam response |
| Biomarker | Test | Clinical | Optimal Goal |
|---|---|---|---|
| NAD⁺ (whole blood) | Jinfiniti Intracellular NAD⁺ | CLINICALNo standard reference | GOAL>40 µM; expect increase on 5-Amino-1MQ |
| CoQ10 (Ubiquinol) | Plasma CoQ10 | CLINICAL0.4–1.9 µg/mL | GOAL1.5–3.5 µg/mL; trending up on SS-31 + MOTS-c |
| GDF-15 Mitochondrial stress | Serum GDF-15 | CLINICAL<1200 pg/mL | GOAL<400 pg/mL; declining trend indicates mito improvement |
| Resting Lactate | Serum Lactate | CLINICAL0.5–2.2 mmol/L | GOAL0.5–1.0 mmol/L |
| Biomarker | Test | Clinical | Optimal Goal |
|---|---|---|---|
| hsCRP | High-sensitivity CRP | CLINICAL<3.0 mg/L | GOAL<0.5 mg/L |
| IL-6 | Serum IL-6 | CLINICAL<7.0 pg/mL | GOAL<1.5 pg/mL |
| 8-OHdG | Urine 8-OHdG | CLINICAL<15 ng/mg creatinine | GOAL<5 ng/mg creatinine |
| Biomarker | Test | Clinical | Optimal Goal |
|---|---|---|---|
| Nocturnal Melatonin Epithalon pineal marker | Urine 6-sulfatoxymelatonin | CLINICALDeclines with age | GOALUpper quartile for age; increasing on Epithalon |
| GH (fasting) | Serum Growth Hormone | CLINICALM: <5 / F: <10 ng/mL | GOALMonitor via IGF-1 — do not exceed upper age reference |
| TSH / Free T3 | Thyroid panel | CLINICALTSH 0.4–4.0 mIU/L | GOALTSH 1.0–2.5; Free T3 upper third of range |
| Biomarker | Test | Clinical | Optimal Goal |
|---|---|---|---|
| BDNF | Serum BDNF (fasting AM) | CLINICAL~10,000–30,000 pg/mL | GOALUpper half of lab range; trending up on Semax cycles |
| Biomarker | Test | Clinical | Optimal Goal |
|---|---|---|---|
| AST / ALT | CMP | CLINICALAST 10–40 / ALT 7–56 U/L | GOALAST <26 / ALT <26 U/L |
| CBC with differential | Complete Blood Count | CLINICALStandard ranges | GOALMid-range; WBC 4.5–6.0; stable across the year |
| Lipid Panel (advanced) | apoB, LDL-P, TG, HDL | CLINICALStandard lipid references | GOALapoB <60 / TG <80 / HDL >60 |
| Fasting Glucose / Insulin | Fasting glucose + insulin | CLINICALGlucose 70–99 / Insulin 2–25 | GOALGlucose 75–90 / Insulin 2–6 / HOMA-IR <1.0 |